<DOC>
	<DOCNO>NCT00842140</DOCNO>
	<brief_summary>The purpose study assess early marker cardiovascular disease woman polycystic ovary syndrome use oral contraceptive contain ethynilestradiol chlormadinone acetate alone associate Spironolactone .</brief_summary>
	<brief_title>Safety Hormonal Contraceptives Therapies Polycystic Ovary Syndrome ( PCOS ) Women</brief_title>
	<detailed_description>Polycystic ovary syndrome ( PCOS ) associate comorbidities may contribute increase risk cardiovascular disease ( CVD ) . Oral contraceptive ( OC ) mainstay PCOS pharmacological therapy decade . However , non-hyperandrogenic woman , OC use associate high risk cardiovascular disease , raise concern possible worsen unfavorable metabolic cardiovascular profile PCOS patient . There lack evidence impact PCOS pharmacological therapy cardiovascular risk marker long-term safety drug PCOS establish . The aim study compare effect OC alone associate anti-androgenic drug ( spironolactone ) echografic cardiovascular risk marker , metabolic hemostatic variable .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Chlormadinone Acetate</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<criteria>age 18 35 year diagnosis PCOS Rotterdam Consensus smoking , alcoholism , drug addiction ; current pregnancy ; current previous use ( two month study ) oral , vaginal , monthly injectable , transdermal combine hormonal contraceptive ; current previous use ( six month study ) longlasting hormonal contraceptive method ( injectable , implant , intrauterine device ) ; antiandrogenic hypoglycemic drug , antiinflammatory drug , statin ; presence systemic disease ( DM2 , cardiovascular disease , autoimmune disease , liver disease , thyroid disease , congenital renal hyperplasia ) ; personal history arterial venous thrombosis ; chronic acute inflammatory process ; puerperium 12 week less</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Polycystic ovary syndrome</keyword>
	<keyword>Oral Contraceptives , Hormonal</keyword>
	<keyword>Cardiovascular Disease</keyword>
	<keyword>Endothelium</keyword>
</DOC>